PROJECT DESCRIPTION
During the five-year project funding period, CELLS employees will focus on legal and social aspects of the project. In addition to the development and evaluation of the live remote training program, another goal of the project is to use this program to reduce the long-term consequences for patients undergoing cancer therapy. At this point, symptoms or side effects such as fatigue, low physical fitness or nerve damage can be mentioned as examples.
The project start of PREFERABLE-II was in November 2022. During the kick-off meeting in Utrecht in November 2022, the different work packages of the project were presented and the consortium could get to know each other personally and exchange further ideas for the collaboration. PREFERABLE-II is coordinated by Prof. Dr. Anne May from UMC Utrecht. Other colleagues from Australia, Belgium, Germany, the Netherlands, Portugal, Sweden and Spain are also involved. We look forward to further collaboration on this important topic!
This project is funded by the European Union and co-funded by a grant from the National Health and Medical Research Council of the Australian Government (grant ID 2017666).
Contact
For further information please do not hesitate to contact our contact person.
30159 Hannover
